A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 6, 2008, Pages 1103-1109

  Nakajo, Akihiro ^a   Hokita, Shuichi ^a   Ishigami, Sumiya ^a   Miyazono, Futoshi ^a   Etoh, Tadaaki ^b   Hamanoue, Masahiro ^c   Maenohara, Shigeho ^c   Iwashita, Toshimitsu ^d   Komatsu, Hideaki ^e   Satoh, Kiyoharu ^f   Aridome, Kuniaki ^g   Morita, Satoshi ^h   Natsugoe, Shoji ^a   Takiuchi, Hiroya ⁱ   Nakano, Shyuji ^j   Maehara, Yoshihiko ^j   Sakamoto, Junichi ^h   Aikou, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Kagoshima Kouseiren Hospital   (Japan)

^d Kitakyushu Medical Center   (Japan)

^e Sasebo Shiritsu Sogo Hospital   (Japan)

^f SAGA UNIVERSITY   (Japan)

^g Saiseikai Sendai Hospital   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ OSAKA MEDICAL COLLEGE   (Japan)

^j KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Advanced gastric cancer; Chemotherapy; Paclitaxel; Phase II; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FATIGUE; FEMALE; FEVER; HUMAN; HYPONATREMIA; INOPERABLE CANCER; LEUKOPENIA; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SODIUM BLOOD LEVEL; STOMACH CANCER; STOMATITIS; VOMITING;

ADENOCARCINOMA; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPONATREMIA; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; OXONIC ACID; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR;

EID: 51849120327     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0693-y     Document Type: Article

References (20)

1. A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thum American Cancer Society 2004 Cancer statistics CA Cancer J Clin 54 8 29
2. P Pisani DM Parkin F Bray J Ferlay 1999 Erratum: estimates of the worldwide mortality from 25 cancers in 1990 Int J Cancer 83 18 29
3. W Koizumi S Tanabe K Saigenji A Ohtsu N Boku F Nagashima K Shirao Y Matsumura M Gotoh 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 12
4. K Yoshida M Ninomiya N Takakura N Hirabayashi W Takiyama Y Sato S Todo M Terashima M Gotoh J Sakamoto M Nishiyama 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 7
5. M Inokuchi T Yamashita H Yamada K Kojima W Ichikawa Z Nihei T Kawano K Sugihara 2006 Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer Br J Cancer 94 1130 5
6. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41
7. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 91
8. B Glimelius K Ekstrom K Hoffman W Graf PO Sjoden U Haglund C Svensson LK Enander T Linne H Sellstrom R Heuman 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 8
9. T Takechi K Nakano J Uchida A Mita K Toko S Takeda N Unemi T Shirasaka 1997 Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats Cancer Chemother Pharmacol 39 205 11
10. M Fukushima H Satake J Uchida Y Shimamoto T Kato T Takechi H Okabe A Fujioka K Nakano H Ohshimo S Takeda T Shirasaka 1998 Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693 8
11. H Fujiwara M Terashima T Irinoda A Takagane K Abe T Nakaya H Yonezawa K Oyama M Takahashi K Saito T Takechi M Fukushima T Shirasaka 2003 Superior antitumor activity of S-1 in tumors with a high dihydropyrimidine dehydrogenase activity Eur J Cancer 39 2387 94
12. Y Sakata A Ohtsu N Horikoshi 2005 Late phase II study of novel oral fluoropyrimidine anti cancer drug S-1 in advanced and recurrent gastrointestinal cancer Eur J Cancer 34 1715 1720
13. PB Schiff SB Horwitz 1981 Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins Biochemistry 20 3247 52
14. M De Brabander G Geuens R Nuydens R Willebrords J De Mey 1981 Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores Proc Natl Acad Sci USA 78 9 5608 612
15. K Yamaguchi M Tada N Horikoshi T Otani H Takiuchi S Saitoh R Kanamaru Y Kasai W Koizumi Y Sakata T Taguchi Paclitaxel Gastric Cancer Study Group in Japan 2002 Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90 5
16. S Hokita T Aikou F Miyazono S Ishigami K Aridome S Maenohara T Saihara K Suenaga H Nomura S Maeda H Takatori H Arima Y Uchikado S Natsugoe S Takao 2006 A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer Cancer Chemother Pharmacol 57 736 40
17. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Natl Cancer Inst 92 205 16
18. E Mochiki T Ohno Y Kamiyama R Aihara N Haga H Ojima J Nakamura H Ohsawa T Nakabayashi K Takeuchi T Asao H Kuwano North Kanto Gastric Cancer Study Group 2006 Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer Br J Cancer 95 1642 7
19. A Nakajo S Natsugoe S Hokita S Ishigami H Takatori T Arigami Y Uenosono K Aridome T Aikou 2007 Successful treatment of advanced gastric cancer by surgical resection following combination chemotherapy with oral S-1 and biweekly paclitaxel Gastric Cancer 10 58 62
20. H Takiuchi M Goto S Kawabe S Ohta K Katsu 2005 Second-line chemotherapy in gastric cancer Jpn J Cancer Chemo 32 19 23